Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06629779 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT06629779 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 900 participants, above the 185-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (386% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT06629779, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Enzalutamide
- DRUG PF-06821497
Study Locations (20)
Arizona
- Ironwood Cancer & Research Centers - Chandler
- Ironwood Cancer & Research Centers - Gilbert
- Palo Verde Hematology Oncology - Glendale
- Ironwood Cancer & Research Centers - Glendale
- Ironwood Cancer & Research Centers - Goodyear
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Phoenix
- Ironwood Cancer & Research Centers - Scottsdale
California
- Los Angeles Cancer Network (LACN) - Anaheim
- Los Angeles Cancer Network (LACN) - Fountain Valley
- Los Angeles Cancer Network (LACN) - Glendale
- Los Angeles Cancer Network (LACN) - Glendale
- Los Angeles Cancer Network (LACN) - Los Angeles
- Los Angeles Cancer Network (LACN) - Los Angeles
- Medical Oncology Associates of San Diego - San Diego
Arkansas
- Highlands Oncology - Fayetteville
- Arkansas Urology - Little Rock - Little Rock
- Highlands Oncology - Rogers
- Highlands Oncology Group - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06629779
The ClinicalTrials.gov registry entry for NCT06629779 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 185-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (386% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06629779 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Arizona, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06629779 about?
NCT06629779 is a clinical study titled "A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.". This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
What is the current status of trial NCT06629779?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2024-10-22. Estimated completion is 2028-11-30.
What conditions does trial NCT06629779 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT06629779?
The interventions under investigation include: Placebo (DRUG), Enzalutamide (DRUG), PF-06821497 (DRUG).
Who is sponsoring clinical trial NCT06629779?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06629779 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
RECRUITING · Phase 3
-
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
ACTIVE NOT RECRUITING · Phase 3
-
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.